GlassScriptPhysician profile
Staycha Lee
NPI 1346817061
$2,262.26
in general payments reported to CMS, 2019-2025
24 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $678 · 2023: $466 · 2024: $393 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.76 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $234.87 | 2022 | |
| Lilly USA, LLC | $139.44 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $135.71 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $133.06 | 2021 | |
| Glaxosmithkline, LLC. | $89.21 | 2021-2025 | Shingrix |
| Janssen Pharmaceuticals, INC | $82.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.47 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Boston Scientific Corporation | $73.30 | 2022-2024 | Artisan |
| Organon LLC | $54.73 | 2023-2025 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $52.57 | 2023 | Farxiga |
| Lucid Diagnostics INC. | $43.71 | 2023 | |
| Axsome Therapeutics, INC. | $25.60 | 2023 | Auvelity |
| Inogen, INC. | $22.42 | 2024 | |
| Neurocrine Biosciences, INC. | $19.28 | 2024 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.00 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $17.61 | 2023 | |
| Merck Sharp & Dohme LLC | $16.71 | 2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Idorsia Pharmaceuticals US INC | $15.41 | 2023 | Quviviq |
| Medtronic, INC. | $15.13 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.76 | 2025 | |
| Antares Pharma, INC. | $13.87 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $13.37 | 2024 | Voquezna |
| Novo Nordisk INC | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staycha Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.